2,4,6-三溴苯基硫脲 | 5337-47-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硫脲
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4,6-三溴苯基硫脲
• 中文别名: 2,4,6-三溴苯(基)硫脲
• 英文名称: 1-(2,4,6-tribromophenyl)thiourea
• 英文别名: (2,4,6-tribromo-phenyl)-thiourea；(2,4,6-Tribrom-phenyl)-thioharnstoff；N-(2,4,6-Tribromophenyl)thiourea；(2,4,6-tribromophenyl)thiourea
• CAS: 5337-47-3
• 化学式: C₇H₅Br₃N₂S
• 分子量: 388.908
• InChiKey: ACUIIYNEUHWWGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险类别码：
  R22
• 海关编码：
  2930909090
• 安全说明：
  S22,S36/37

反应信息

• 作为反应物：
  描述：

  2,4,6-三溴苯基硫脲 在 三甲基铝 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 30.0h， 生成 2-(2,4,6-Tribromo-phenylamino)-4-trifluoromethyl-thiazole-5-carboxylic acid cyclopropylmethyl-propyl-amide
  参考文献：
  名称：

  2-Arylaminothiazoles as high-affinity corticotropin-Releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy

  摘要：

  2-Arylamino-4-trifluoromethyl-5-aminomethylthiazoles represent a novel series of high-affinity corticotropin releasing factor-1 receptor (CRF1R) antagonists that are prepared in three steps in good overall yields. Herein, we report binding SAR as well as anxiolytic activity of an exemplary compound (7a, K-i = 8.6 nM) in a mouse canopy model. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.055
• 作为产物：
  描述：

  2,4,6-三溴苯胺 在 sodium hydroxide 作用下， 生成 2,4,6-三溴苯基硫脲
  参考文献：
  名称：

  The Preparation and Hydrolysis of Mono- and Disubstituted Benzoylthioureas¹

  摘要：

  DOI：

  10.1021/ja01321a061

文献信息

• Discovery of aryl aminothiazole γ-secretase modulators with novel effects on amyloid β-peptide production
  作者：Sanjay Bhattarai、Lei Liu、Michael S. Wolfe

  DOI：10.1016/j.bmcl.2021.128446

  日期：2021.12

  A series of analogs based on a prototype aryl aminothiazole γ-secretase modulator (GSM) were synthesized and tested for their effects on the profile of 37-to-42-residue amyloid β-peptides (Aβ), generated through processive proteolysis of precursor protein substrate by γ-secretase. Certain substitutions on the terminal aryl D ring resulted in an altered profile of Aβ production compared to that seen

  合成了一系列基于原型芳基氨基噻唑 γ-分泌酶调节剂 (GSM) 的类似物，并测试了它们对通过前体蛋白的持续蛋白水解产生的 37 至 42 残基淀粉样蛋白 β 肽 (Aβ) 的影响γ-分泌酶的底物。与母体分子相比，末端芳基 D 环上的某些取代导致 Aβ 产生的变化。微小的结构变化导致 Aβ37 和 Aβ38 产量的浓度依赖性增加，而它们的前体 Aβ40 和 Aβ42 分别没有平行减少。因此，新化合物显然也刺激了 Aβ 肽的羧肽酶修剪≥ 43 个残基，为 γ-分泌酶进行性蛋白水解的机理研究提供了新的化学工具。
• Discovery of aminothiazole derivatives as novel human enterovirus A71 capsid protein inhibitors
  作者：Zhichao Xu、Qi Tang、Ting Xu、Yang Cai、Ping Lei、Yinuo Chen、Wenting Zou、Chune Dong、Ke Lan、Shuwen Wu、Hai-Bing Zhou

  DOI：10.1016/j.bioorg.2022.105683

  日期：2022.5

  Enterovirus A71 (EV-A71), one of the major pathogens that causes hand, foot and mouth disease (HFMD), has seriously threatened the health and safety of young children. In this study, aminothiazole derivatives were synthesized and screened against EV-A71 in Rhabdomyosarcoma (RD) cells. The best compound (12s), with a biphenyl group, showed activity against EV-A71 (EC50: 0.27 μM) but also against a series

  肠道病毒 A71 (EV-A71) 是导致手足口病 (HFMD) 的主要病原体之一，严重威胁幼儿的健康和安全。在这项研究中，合成了氨基噻唑衍生物，并在横纹肌肉瘤 (RD) 细胞中针对 EV-A71 进行了筛选。最好的化合物 ( 12 s )，带有一个联苯基，对 EV-A71 (EC 50 : 0.27 μM) 显示出活性，而且对一系列不同的人类肠道病毒也没有显着的细胞毒性 (CC 50  > 56.2 μM)。包括药物添加时间测定、病毒进入测定和微量热泳 (MST) 实验在内的机制研究表明，12 s与 EV-A71 衣壳结合并阻断病毒蛋白 VP1 与相关的人类清道夫受体 B 类成员 2 (hSCARB2) 之间的结合。
• METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES
  申请人：Imam Abdulrahman Bin Faisal University

  公开号：US20200102228A1

  公开（公告）日：2020-04-02

  Methods of synthesizing Bi 2 S 3 —CdS particles in the form of spheres as well as properties of these Bi 2 S 3 —CdS particles are described. Methods of photocatalytic degradation of organic pollutants employing these Bi 2 S 3 —CdS particles and methods of preventing or reducing microbial growth on a surface by applying these Bi 2 S 3 —CdS particles in the form of a solution or an antimicrobial product onto the surface are also specified.

  本文描述了合成球形Bi2S3-CdS颗粒的方法以及这些颗粒的性质。还介绍了利用这些Bi2S3-CdS颗粒进行光催化降解有机污染物的方法，以及通过将这些Bi2S3-CdS颗粒以溶液或抗微生物产品的形式涂布在表面上来防止或减少微生物生长的方法。
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• Novel quinazoline derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20070010671A1

  公开（公告）日：2007-01-11

  The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(1)，并作为MCH受体拮抗剂。这些化合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴食障碍（包括贪食症、厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆）、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。